Compare Novo Nordisk A/S (NVO) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Virgin Galactic Holdings, Inc. — how do they compare? Novo Nordisk A/S trades at $45.97 (market cap $207.85B), while Virgin Galactic Holdings, Inc. trades at $3.27 (market cap $498.02M). The key difference: Novo Nordisk A/S is far larger — about 417.4× Virgin Galactic Holdings, Inc.'s market cap, and Novo Nordisk A/S pays a 3.81% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| NVO | SPCE | |
|---|---|---|
Market Cap | $207.85B | $498.02M |
Sector | Health | Industrials |
52-Week High | $63.98 | $7.52 |
52-Week Low | $35.29 | $2.17 |
Enterprise Value | $222.55B | $597.87M |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Virgin Galactic (SPCE) trades at $3.23, up 4.19% on the day, with a bullish technical signal from moving averages but overbought RSI levels near 91.63. The company continues to report significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations of $240.14 million. Recent news highlights focus on upcoming Q2 2026 earnings and sector volatility amid SpaceX's market debut.
The outlook remains high-risk due to persistent unprofitability and cash burn, though recent quarterly EPS beats offer some optimism. Investment opportunity hinges on successful commercialization of space tourism, while risks include intense competition, funding needs, and execution challenges. Analyst sentiment is mixed with 29.41% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
